Form 4: MAIA Director Stan Smith Buys Shares

MAIA Biotechnology Director Stan Smith acquired 13,740 shares of common stock through family trusts under a Rule 10b5-1 plan.

Summary

• Stan Smith, a Director of MAIA Biotechnology, Inc. (MAIA), purchased common stock.
• The transactions occurred on December 5, 2025.
• A total of 13,740 shares were acquired across three separate indirect holdings.
• These purchases were made through the Travis Deo Zai Zai Smith IL Unif Trns Min Act, the Gage Quentin Smith IL Unif Trns Min Act, and the Blake Sarai Teitei Smith IL Unif Trns Min Act.
• Each of these three trusts acquired 4,580 shares.
• The purchase prices were $1.1997, $1.19, and $1.2 per share, respectively.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.
• Following these transactions, Mr. Smith's total indirect beneficial ownership, including shares held by The Stan V. Smith Trust Dated 1993 (1,364,289 shares), amounts to 1,378,029 shares.

Sentiment

Score: 7

Explanation: The purchase of shares by a director is generally a positive signal, indicating confidence in the company's future. The Rule 10b5-1 plan suggests a pre-planned strategy rather than an opportunistic buy, which is neutral to slightly positive.

Positives

• A company director, Stan Smith, purchased shares, which can signal confidence in the company's future prospects.
• The purchases were made at prices ranging from $1.19 to $1.2 per share.
• The transactions were executed under a Rule 10b5-1 plan, indicating a pre-planned acquisition strategy.

Future Outlook

The filing does not contain specific forward-looking statements or guidance, as it primarily reports past insider transactions.

Industry Context

Insider purchases, especially by directors, are often viewed positively by the market as they can signal management's belief in the company's undervaluation or strong future prospects. This transaction by a director of MAIA Biotechnology aligns with general market observations where insider buying can precede positive company developments, though it is not a guarantee.

Comparison to Industry Standards

• Insider buying activity is a common occurrence across all industries. While the specific volume of shares purchased by Director Smith is notable for MAIA Biotechnology, it is difficult to compare directly to specific projects or results of other companies without more context on MAIA's market capitalization and the director's overall compensation structure.
• Director purchases are generally seen as a positive signal, consistent with similar actions observed in other biotechnology firms where management demonstrates confidence through personal investment.

Related Party Transactions

• The shares were acquired indirectly through trusts for family members (Travis Deo Zai Zai Smith IL Unif Trns Min Act, Gage Quentin Smith IL Unif Trns Min Act, Blake Sarai Teitei Smith IL Unif Trns Min Act).
• Mr. Smith disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
• Additional shares are beneficially owned through The Stan V. Smith Trust Dated 1993.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive indicator of management confidence, potentially leading to increased investor interest.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Recommendation

While insider buying by a director is generally a positive signal, indicating confidence in the company's prospects, this specific transaction was executed under a Rule 10b5-1 plan, suggesting it was pre-scheduled rather than a reactive, opportunistic buy. Without additional context on MAIA Biotechnology's recent performance, strategic developments, or broader market conditions, this single insider purchase, while positive, is not sufficient to warrant a 'buy' recommendation. A 'hold' recommendation is appropriate, suggesting investors maintain their current position while awaiting further fundamental news or a more significant pattern of insider activity.

Keywords

MAIA Biotechnology, MAIA, Stan Smith, Director, Insider Trading, Stock Purchase, Form 4, Beneficial Ownership, Rule 10b5-1, Common Stock